Results 1 to 10 of about 3,690 (153)

Cefiderocol

Revista Española de Quimioterapia, 2022
Cefiderocol is a new siderophore cephalosporin with potent in vitro activity against gram-negative bacilli including Enterobacterales that produce all kinds of carbapenemases and non-fermenting Gram-negative with difficult-to-treat resistance. As a β-lactam, its efficacy is optimized in extended-perfusion and requires dose adjustment in renal ...
Soriano, María Cruz, Montufar, Jessie, Blandino-Ortiz, Aaron   +2 more
  +5 more sources

New mutations in genes associated with cefiderocol resistance in a clinical isolate of Pseudomonas aeruginosa [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
Objective. To assess the effects of chromosomal mutations on emergence of cefiderocol resistance among Pseudomonas aeruginosa clinical isolates. Materials and Methods.
Bocharova Yu.A., Savinova T.A., Mayansky N.A., Chebotar I.V.   +3 more
doaj   +1 more source

Cefiderocol Resistance in Klebsiella pneumoniae Is Linked to SHV Extended-Spectrum β-Lactamase Activities and Functional Loss of the Outer Membrane Porin OmpK35

Microbiology Spectrum, 2023
Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin.
Sun Hee Moon, En Huang
doaj   +1 more source

Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China

Microbiology Spectrum, 2022
Cefiderocol is a novel siderophore cephalosporin exhibiting potent antimicrobial activities. Although cefiderocol has not been approved in China, resistance is emerging.
Peng Lan, Ye Lu, Zhongju Chen, Xueqing Wu, Xiaoting Hua, Yan Jiang, Jiancang Zhou, Yunsong Yu   +7 more
doaj   +1 more source

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

Frontiers in Pharmacology, 2022
Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial iron transport systems facilitating drug entry into cells, achieving high periplasmic concentrations.
Chuanhai Wang, Deqing Yang, Yifan Wang, Wentao Ni   +3 more
doaj   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program

Microbiology Spectrum, 2022
Cefiderocol is a siderophore-conjugated cephalosporin with broad activity against Gram-negative (GN) bacteria, including carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa, Acinetobacter spp., and Stenotrophomonas maltophilia ...
Dee Shortridge, Jennifer M. Streit, Rodrigo Mendes, Mariana Castanheira   +3 more
doaj   +1 more source

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019

Microbiology Spectrum, 2022
Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019).
James A. Karlowsky, Andrew J. Walkty, Melanie R. Baxter, Heather J. Adam, Philippe R. S. Lagacé-Wiens, Frank Schweizer, Denice Bay, Joseph P. Lynch, Michael R. Mulvey, George G. Zhanel   +9 more
doaj   +1 more source

In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018

Journal of Global Antimicrobial Resistance, 2021
: Objectives: The prevalence of Gram-negative bacteria (GNB) demonstrating extensive, multiple antimicrobial resistance is increasing in England, leaving few treatment choices.
Vanya Gant, Abid Hussain, Malcolm Bain, Christopher Longshaw, Anne Santerre Henriksen   +4 more
doaj   +1 more source

Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations

IDCases, 2020
Cefiderocol is a novel siderophore cephalosporin antibacterial with activity against carbapenem-resistant Gram-negative bacteria including Pseudomonas aeruginosa.
Wesley D. Kufel, Jeffrey M. Steele, Scott W. Riddell, Zachary Jones, Pegah Shakeraneh, Timothy P. Endy   +5 more
doaj   +1 more source